Continuing the Transition Plan ... Optimizing Quality of Life and Outcomes

This activity has expired.
Release Date: September 23, 2016
Expiration Date: September 23, 2017
Estimated Time to Complete Activity: 60
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)
Target Audience

This activity has been designed to meet the educational needs of hematologists, pediatricians, adolescent medicine subspecialists, registered nurses, advanced practice registered nurses, social workers, and primary care physicians who treat patients with congenital bleeding disorders; health care providers (HCPs) practicing in a hemophilia treatment center (HTC); and other clinicians who inherit transitioning patients with hemophilia in new settings (such as primary care practices, university/college medical services, and new hematology environments).

Statement of Need/Program Overview

Transition is defined as “the purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented health care systems.” This transition from dependent child to independent adult is well recognized as a gradual process that takes several years and requires continuing care and support.

Despite such recognition, arrangements for transfer into the adult sector are quite variable, and facilities for adolescents and young adults in both the pediatric and adult setting are often unsatisfactory.

Thus, transition for the hemophilia patient is an ongoing journey from young child to preteen to adolescent to young adult, and finally, to older adult, with each stage having its own dynamics, issues, and challenges for both the patient and the health care providers.
Treatment in hemophilia is designed to reduce bleed frequency, minimize joint damage, and maximize functional independence and quality of life. For most patients, prophylaxis may be the preferred regimen, but there are issues with adherence and other barriers such as cost and lifestyle that must be addressed with personalized management plans.

HCPs need updates to their knowledge about and competence in understanding the unique needs of patients as they transition through these life phases, and they need to able to provide appropriate counseling and relevant education about treatment options and adherence to the prescribed therapy in order to achieve positive outcomes and quality of life.

Educational Objectives
After participating in this activity, participants should be able to:
  • Discuss issues and challenges associated with administration of prophylaxis factor concentrates, including novel factor replacement products with extended half-lives
  • Evaluate strategies for enhancing adherence to prophylaxis treatment regimens in patients with hemophilia (PWH)
  • Implement an individualized care approach with transitioning adolescents and young adults as well as older PWH
  • Initiate a comprehensive multidisciplinary assessment of the physical, emotional, and social status of adult PWH

Presenting Faculty

Mark T. Reding, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Margaret Heisel Kurth, MD
Director Emeritus, Center for Bleeding and Clotting Disorders
Children’s Hospitals and Clinics of Minnesota
Clinical Assistant Professor
Department of Pediatrics
University of Minnesota Medical School
Minneapolis, Minnesota

Susan D. Purdie, RN, CPHON
Hematology Nurse Case Manager
Hemophilia and Thrombosis Center
Children’s Hospitals and Clinics of Minnesota
Minneapolis, Minnesota

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for .8 contact hours is provided by Postgraduate Institute for Medicine. 
Designated for .4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Social Worker Continuing Education
This program is Approved by the National Association of Social Workers (Approval # 886742208-2678) for 1 continuing education contact hours.

Method of Participation
During the period of September 23, 2016 through September 23, 2017, participants must:
  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form

A statement of credit will be issued automatically upon successfully completing the post-activity survey with a score of 75% or better and submitting the activity evaluation.

Fee Information
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Mark Reding, MD

Consulting Fees: Baxter, Bayer HealthCare, Biogen Idec, Novo Nordisk; Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Baxalta and Biogen Idec; Contracted Research: Bayer HealthCare.

Margaret Heisel Kurth, MD Has no real or apparent conflicts of interest to report.
Susan Purdie, RN

Has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; Jan Schultz, RN, MSN, CHCP

Have no real or apparent conflicts of interest to report.

Educational Concepts in Medicine: Patrick J. Crowley, MBA, President/CEO; Jodi Andrews, Vice President, Operations; Larry Rosenberg PhD, Medical Writer Have no real or apparent conflicts of interest to report.


Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc